Blurbs

Analysts Offer Insights on Healthcare Companies: Haemonetics (HAE), Alcon (ALC) and Zentalis Pharmaceuticals (ZNTL)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Haemonetics (HAEResearch Report), Alcon (ALCResearch Report) and Zentalis Pharmaceuticals (ZNTLResearch Report).

Haemonetics (HAE)

In a report released today, Drew Ranieri from Morgan Stanley maintained a Hold rating on Haemonetics, with a price target of $74.00. The company’s shares closed last Thursday at $73.75, close to its 52-week high of $77.08.

According to TipRanks.com, Ranieri is a 1-star analyst with an average return of -4.8% and a 42.4% success rate. Ranieri covers the Healthcare sector, focusing on stocks such as Treace Medical Concepts, Baxter International, and Integra Lifesciences.

Currently, the analyst consensus on Haemonetics is a Moderate Buy with an average price target of $82.80, an 11.8% upside from current levels. In a report released yesterday, Needham also maintained a Hold rating on the stock.

See the top stocks recommended by analysts >>

Alcon (ALC)

In a report released today, Cecilia Furlong from Morgan Stanley maintained a Hold rating on Alcon, with a price target of $81.00. The company’s shares closed last Thursday at $70.57.

According to TipRanks.com, Furlong is a 5-star analyst with an average return of 20.6% and a 51.4% success rate. Furlong covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Bausch + Lomb Corporation, and Zimmer Biomet Holdings.

Alcon has an analyst consensus of Moderate Buy, with a price target consensus of $80.71, implying a 12.6% upside from current levels. In a report released today, Societe Generale also downgraded the stock to Hold with a CHF73.60 price target.

Zentalis Pharmaceuticals (ZNTL)

Morgan Stanley analyst Matthew Harrison maintained a Buy rating on Zentalis Pharmaceuticals today and set a price target of $60.00. The company’s shares closed last Thursday at $27.72, close to its 52-week low of $17.33.

According to TipRanks.com, Harrison is a 5-star analyst with an average return of 7.8% and a 53.2% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, BioMarin Pharmaceutical, and Vertex Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zentalis Pharmaceuticals with a $61.40 average price target, a 107.9% upside from current levels. In a report issued on July 27, SVB Securities also maintained a Buy rating on the stock with a $67.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on HAE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More